Physiopathologie et traitement de la vasoplégie au cours du sepsis [Pathophysiological mechanisms and treatment of septic shock-induced vasoplegia]

Détails

Ressource 1Télécharger: RMS_idPAS_D_ISBN_pu2011-45s_sa03_art03.pdf (1579.52 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_403B2736CABB
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Physiopathologie et traitement de la vasoplégie au cours du sepsis [Pathophysiological mechanisms and treatment of septic shock-induced vasoplegia]
Périodique
Revue Médicale suisse
Auteur⸱e⸱s
Jeanneret S. (co-premier), Sanchez B. (co-premier), Liaudet L.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
14/12/2011
Peer-reviewed
Oui
Volume
7
Numéro
321
Pages
2435-2438
Langue
français
Notes
Publication types: English Abstract ; Journal Article ; Review
Publication Status: ppublish
Résumé
The hemodynamics of septic shock is characterized by a primary reduction of vascular tone, which defines vasoplegia. Septic vasoplegia is due to reduced endogenous production of vasopressin, as well as to the overproduction of vasodilating molecules (nitric oxide, prostacyclin, peroxynitrite and kynurenine) and the opening of ATP-sensitive potassium channels. Treatment is supportive and includes primarily alpha-adrenergic catecholamines. Vasopressin may also be useful, although its place is still controversial. Further agents can improve the vascular responsiveness to catecholamines, most notably low doses hydrocortisone, and, to a lesser extent, activated protein C. Further, innovative therapies, based on recent understanding of pathophysiological mechanisms, might become useful agents to treat septic vasoplegia in the future.
Mots-clé
Catecholamines/therapeutic use, Humans, Hydrocortisone/therapeutic use, KATP Channels/metabolism, KATP Channels/physiology, Models, Biological, Nitric Oxide/adverse effects, Nitric Oxide/metabolism, Nitric Oxide/physiology, Peroxynitrous Acid/adverse effects, Peroxynitrous Acid/metabolism, Peroxynitrous Acid/physiology, Prostaglandins I/adverse effects, Prostaglandins I/metabolism, Prostaglandins I/physiology, Protein C/therapeutic use, Shock, Septic/complications, Shock, Septic/metabolism, Shock, Septic/therapy, Signal Transduction/physiology, Vasoplegia/etiology, Vasoplegia/metabolism, Vasoplegia/therapy, Vasopressins/therapeutic use
Pubmed
Création de la notice
02/05/2019 7:10
Dernière modification de la notice
25/11/2024 12:56
Données d'usage